The pharmaceutical industry sees the Finnish EU Presidency as an opportunity to promote the European competitiveness
The pharmaceutical industry sees the Finnish EU Presidency as an opportunity to promote the European competitiveness. The agenda for the forthcoming EU Commission will include important issues related to research, innovations and the industrial policy.
3rd Nordic conference will facilitate and bring forward ideas for discussion in order to accelerate medicine development for children, by providing most appropriate context for new solutions, and updating the current information related to pediatric Clinical Trials.
Syöpäsäätiö (Cancer Foundation) and thirty-two other research actors provided the parliamentary groups with their appeal for enhanced medical research.
In 2018, the R&D investments made by the pharmaceutical industry in Finland grew by over six percent. The aggregate investment of the pharmaceutical industry in research and development in 2018 was over 216 million euro, compared to 201 million euro in the previous year.
We in the pharmaceutical industry want to contribute to medical breakthroughs and ensure that they are exploited in the best interest of the patients. During the operating year 2018, we set the step marks for the future and drafted our new strategy for the years 2019-2021.